Pharmafile Logo
Pharmafocus logo
Advanced Search

cannabis

Showing 13 posts of 28 posts found.

cannabis-2152604_960_720

Australian firm Althea enters UK medicinal cannabis market

February 13, 2019
Research and Development Epidiolex, GW Pharma, Medical marijuana, NHS, UK, cannabis

Melbourne-based medicinal cannabis company Althea has become one of the first companies to enter the UK market after the British …

News

Novartis inks deal with Canadian cannabis firm Tilray

December 18, 2018
Research and Development Marijuana, Novartis, Sandoz, Tilray, cannabis

Shares in Canadian cannabis company Tilray jumped by more than 11% today after the British Columbia-based firm announced its entry …

News
gwpharma

GW Pharma’s Epidiolex becomes first cannabis-based medicine to be made available in United States

November 2, 2018
Medical Communications Epidiolex, GW Pharma, Medical marijuana, cannabidiol, cannabis

GW Pharma’s Epidiolex has become the first plant-derived, cannabis-based medicine to be made available on prescription in all 50 US …

News
medicinal_cannabis_uk_review

Medical Marijuana to be legalised in Thailand and Malaysia as drug becomes available on prescription in UK

November 1, 2018
Business Services, Medical Communications Medical marijuana, UK, cannabis, malaysia, thailand

Thailand’s public health ministry is working to make medical marijuana legal by next month. The shift is expected to come …

News
Scientist looking at medicinal cannabis in a laboratory

Cannabis-derived medicinal products to become available in UK

July 26, 2018
Medical Communications cannabis, law, medicinal marijuana, prescription, sajid javid, schedule drugs, uk politics

Home Secretary Sajid Javid has announced that cannabis derived medicinal products will be made available on prescription “by the autumn” …

News
medicinal_cannabis_uk_review

European cannabis market set to be worth €115.7 billion by 2028

July 16, 2018
Sales and Marketing Europe, Legislation, cannabis, medicinal marijuana

The European cannabis market is set to be worth €115.7 billion by 2028, according to a report released by the …

News
michel_porro-getty_images

Zynerba’s cannabis-based transdermal patch fails at Phase 1, shares slide 21%

July 6, 2018
Medical Communications, Research and Development GW Pharma, Zynerba, cannabidinol, cannabinol, cannabis, pharma, trial failure

As public focus on the issue of medicinal cannabis continues to grow, Zynerba Pharmaceuticals has announced that its transdermal tetrahydrocannabinol …

News
Medicinal cannabis in a laboratory

Review signals step towards legalisation of medicinal cannabis in UK

July 4, 2018
Research and Development England, cannabis, pharma, review, thc

England’s Chief Medical Officer Dame Sally Davies has concluded that there is “conclusive evidence” that cannabis is medically beneficial for …

News
gwpharma

GW Pharma’s Epidiolex becomes first cannabis-based medicine available in US

June 26, 2018
Manufacturing and Production, Sales and Marketing FDA, GW Pharma, Lennox-Gastaut syndrome, UK, US, cannabidiol, cannabis

In what could prove to be a pivotal decision, UK biotech GW Pharmaceuticals has announced that its oral cannabidiol solution …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

March 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Canada, Celgene, Lundbeck, Marijuana, Novartis, Roche, Vertex, brexit, cannabis, multiple sclerosis, neuroscience, pharma

As me move startlingly quickly towards Easter, it’s time for another Top Ten rundown. This week, Celgene surprised the industry …

News

FDA issues warnings in crackdown on baseless cannabis miracle cures

November 2, 2017
Research and Development, Sales and Marketing FDA, cannabidiol, cannabis, pharma

The FDA has issued a warning over cannabis-based therapies which promise the ability to cure cancer, asserting that such treatments …

News
laboratory

GW Pharma releases positive data on cannabidiol-based Phase III trial

September 28, 2016
Research and Development Epidiolex, GW Pharmaceuticals, Marijuana, Medical marijuana, cannabis

GW Pharmaceuticals’ Epidiolex is designed to treat seizures in a rare form of epilepsy called Lennox-Gaustaut Syndrome. GW pharmaceuticals published …

News
gwpharma

GW Pharma’s cannabis-based epilepsy drug granted orphan designation by FDA

April 21, 2016
Research and Development, Sales and Marketing GW Pharma, cannabis, cannabis-based, epilepsy

GW Pharmaceuticals (NASDAQ: GWPH) has announced that the US Food and Drug Administration has granted its cannabis-based epilepsy drug, Epidiolex …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026